Logo image of BOLT

BOLT BIOTHERAPEUTICS INC (BOLT) Stock Fundamental Analysis

NASDAQ:BOLT - US0977021049 - Common Stock

5.13 USD
-0.17 (-3.21%)
Last: 8/29/2025, 8:08:47 PM
Fundamental Rating

3

BOLT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. BOLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BOLT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BOLT has reported negative net income.
In the past year BOLT has reported a negative cash flow from operations.
In the past 5 years BOLT always reported negative net income.
BOLT had a negative operating cash flow in each of the past 5 years.
BOLT Yearly Net Income VS EBIT VS OCF VS FCFBOLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of BOLT (-73.78%) is worse than 62.89% of its industry peers.
BOLT has a worse Return On Equity (-135.33%) than 60.33% of its industry peers.
Industry RankSector Rank
ROA -73.78%
ROE -135.33%
ROIC N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
BOLT Yearly ROA, ROE, ROICBOLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

BOLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLT Yearly Profit, Operating, Gross MarginsBOLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BOLT has been increased compared to 1 year ago.
Compared to 5 years ago, BOLT has more shares outstanding
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLT Yearly Shares OutstandingBOLT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BOLT Yearly Total Debt VS Total AssetsBOLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

BOLT has an Altman-Z score of -8.98. This is a bad value and indicates that BOLT is not financially healthy and even has some risk of bankruptcy.
BOLT's Altman-Z score of -8.98 is on the low side compared to the rest of the industry. BOLT is outperformed by 70.38% of its industry peers.
There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.98
ROIC/WACCN/A
WACC9.69%
BOLT Yearly LT Debt VS Equity VS FCFBOLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.13 indicates that BOLT has no problem at all paying its short term obligations.
BOLT has a worse Current ratio (3.13) than 62.16% of its industry peers.
BOLT has a Quick Ratio of 3.13. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
BOLT has a Quick ratio (3.13) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
BOLT Yearly Current Assets VS Current LiabilitesBOLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

BOLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.16%, which is quite impressive.
BOLT shows a decrease in Revenue. In the last year, the revenue decreased by -2.36%.
The Revenue has been growing by 103.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.52%
Revenue 1Y (TTM)-2.36%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%41.49%

3.2 Future

BOLT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.73% yearly.
BOLT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.46% yearly.
EPS Next Y19.04%
EPS Next 2Y13.85%
EPS Next 3Y12.12%
EPS Next 5Y5.73%
Revenue Next Year-48.02%
Revenue Next 2Y-31.19%
Revenue Next 3Y13.16%
Revenue Next 5Y14.46%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BOLT Yearly Revenue VS EstimatesBOLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
BOLT Yearly EPS VS EstimatesBOLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BOLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BOLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLT Price Earnings VS Forward Price EarningsBOLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLT Per share dataBOLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as BOLT's earnings are expected to grow with 12.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.85%
EPS Next 3Y12.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BOLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (8/29/2025, 8:08:47 PM)

5.13

-0.17 (-3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10
Inst Owners46.17%
Inst Owner Change-80.83%
Ins Owners0.63%
Ins Owner Change0%
Market Cap9.85M
Analysts74.55
Price Target39.1 (662.18%)
Short Float %4.18%
Short Ratio1.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)4.58%
Min EPS beat(4)-11.25%
Max EPS beat(4)21.57%
EPS beat(8)7
Avg EPS beat(8)10.98%
EPS beat(12)10
Avg EPS beat(12)10.46%
EPS beat(16)13
Avg EPS beat(16)6.88%
Revenue beat(2)1
Avg Revenue beat(2)-21.95%
Min Revenue beat(2)-100%
Max Revenue beat(2)56.1%
Revenue beat(4)2
Avg Revenue beat(4)-3.78%
Min Revenue beat(4)-100%
Max Revenue beat(4)56.1%
Revenue beat(8)5
Avg Revenue beat(8)21.57%
Revenue beat(12)9
Avg Revenue beat(12)49.64%
Revenue beat(16)12
Avg Revenue beat(16)46.05%
PT rev (1m)-4.17%
PT rev (3m)3307.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1675.25%
EPS NY rev (1m)-2.54%
EPS NY rev (3m)-1664.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.29%
Revenue NY rev (1m)2.23%
Revenue NY rev (3m)43.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.71
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-25.86
EYN/A
EPS(NY)-21.39
Fwd EYN/A
FCF(TTM)-30.18
FCFYN/A
OCF(TTM)-30.16
OCFYN/A
SpS1.89
BVpS24.38
TBVpS24.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.78%
ROE -135.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -8.98
F-Score2
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)172.25%
Cap/Sales(3y)12.39%
Cap/Sales(5y)328.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.52%
EPS Next Y19.04%
EPS Next 2Y13.85%
EPS Next 3Y12.12%
EPS Next 5Y5.73%
Revenue 1Y (TTM)-2.36%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%41.49%
Revenue Next Year-48.02%
Revenue Next 2Y-31.19%
Revenue Next 3Y13.16%
Revenue Next 5Y14.46%
EBIT growth 1Y15.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.4%
OCF growth 3YN/A
OCF growth 5YN/A